BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer 2020;122:372-81. [PMID: 31776458 DOI: 10.1038/s41416-019-0657-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Gao F, Wang J, Li C, Xie C, Su M, Zou C, Xie X, Zhao D. Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors. IJGM 2022;Volume 15:3839-49. [DOI: 10.2147/ijgm.s357224] [Reference Citation Analysis]
2 Chen T, Ni N, Yuan L, Xu L, Bahri N, Sun B, Wu Y, Ou WB. Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling. Front Pharmacol 2021;12:686874. [PMID: 34025442 DOI: 10.3389/fphar.2021.686874] [Reference Citation Analysis]
3 Zhou L, Wang H, Liu H, Huang Z, Wang Z, Xiaojun Z, Mu X. The synergistic therapeutic effect of Imatinib and Protein Kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101886] [Reference Citation Analysis]